KR102260346B1 - 피부 치료 및/또는 관리에 유용한 화합물 및 이의 미용 또는 약제 조성물 - Google Patents

피부 치료 및/또는 관리에 유용한 화합물 및 이의 미용 또는 약제 조성물 Download PDF

Info

Publication number
KR102260346B1
KR102260346B1 KR1020157032617A KR20157032617A KR102260346B1 KR 102260346 B1 KR102260346 B1 KR 102260346B1 KR 1020157032617 A KR1020157032617 A KR 1020157032617A KR 20157032617 A KR20157032617 A KR 20157032617A KR 102260346 B1 KR102260346 B1 KR 102260346B1
Authority
KR
South Korea
Prior art keywords
agents
inci
synthesis
agent
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157032617A
Other languages
English (en)
Korean (ko)
Other versions
KR20150143752A (ko
Inventor
안토니오 빈센트 페레르 몬티엘
누리아 알미나나 도메네치
주안 케브리언 푸체
빔 반 덴 네스트
크리스티나 카레노 세라이마
라퀴엘 델가도 곤잘레즈
Original Assignee
루브리졸 어드밴스드 머티어리얼스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 루브리졸 어드밴스드 머티어리얼스, 인코포레이티드 filed Critical 루브리졸 어드밴스드 머티어리얼스, 인코포레이티드
Publication of KR20150143752A publication Critical patent/KR20150143752A/ko
Application granted granted Critical
Publication of KR102260346B1 publication Critical patent/KR102260346B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/044—Suspensions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/068—Microemulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020157032617A 2013-04-15 2014-04-15 피부 치료 및/또는 관리에 유용한 화합물 및 이의 미용 또는 약제 조성물 Active KR102260346B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13382138.9A EP2792684A1 (en) 2013-04-15 2013-04-15 Compounds useful in the treatment and/or care of the skin and their cosmetic or pharmaceutical compositions
EP13382138.9 2013-04-15
PCT/EP2014/057672 WO2014170347A1 (en) 2013-04-15 2014-04-15 Compounds useful in the treatment and/or care of the skin and their cosmetic or pharmaceutical compositions

Publications (2)

Publication Number Publication Date
KR20150143752A KR20150143752A (ko) 2015-12-23
KR102260346B1 true KR102260346B1 (ko) 2021-06-03

Family

ID=48227117

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157032617A Active KR102260346B1 (ko) 2013-04-15 2014-04-15 피부 치료 및/또는 관리에 유용한 화합물 및 이의 미용 또는 약제 조성물

Country Status (9)

Country Link
US (1) US9458194B2 (cg-RX-API-DMAC7.html)
EP (2) EP2792684A1 (cg-RX-API-DMAC7.html)
JP (1) JP6525433B2 (cg-RX-API-DMAC7.html)
KR (1) KR102260346B1 (cg-RX-API-DMAC7.html)
CN (1) CN105408345B (cg-RX-API-DMAC7.html)
AU (1) AU2014255776B2 (cg-RX-API-DMAC7.html)
CA (1) CA2908863C (cg-RX-API-DMAC7.html)
ES (1) ES2639464T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014170347A1 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) * 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US10242871B2 (en) * 2014-10-21 2019-03-26 Nissan Chemical Industries, Ltd. Resist underlayer film-forming composition including a compound having an amino group protected with a tert-butoxycarbonyl group
CA2965525A1 (en) 2014-10-31 2016-05-06 Lubrizol Advanced Materials, Inc. Thermoplastic polyurethane film for delivery of active agents to skin surfaces
US20180116938A1 (en) * 2015-04-06 2018-05-03 Lg Household & Health Care Ltd. Soluble microneedle for delivering proteins or peptides
EP3371238A1 (en) 2015-11-05 2018-09-12 Lubrizol Advanced Materials, Inc. Thermoformable dual network hydrogel compositions
WO2017136600A1 (en) 2016-02-04 2017-08-10 ALASTIN Skincare, Inc. Compositions and methods for invasive and non-invasive procedural skincare
CN106176274B (zh) * 2016-08-26 2020-04-10 深圳市维琪医药研发有限公司 一种具有抗敏作用的多肽组合物
EP3522865A4 (en) 2016-10-04 2020-06-17 Mary Kay Inc. METHOD AND COMPOSITIONS FOR TREATING STRIAE DISTENSAE
BR102017010169A2 (pt) * 2017-05-15 2019-02-26 Remer Consultores Assessoria Empresarial Ltda. composto, intermediário de síntese, uso na preparação de anticonvulsivante, composição farmacêutica anticonvulsivante
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
JP6859363B2 (ja) * 2016-11-30 2021-04-14 株式会社 資生堂 肌特性解析方法
CA3087881A1 (en) 2017-01-17 2018-07-26 Michael David FORREST Therapeutic inhibitors of the reverse mode of atp synthase
FR3065876B1 (fr) * 2017-05-05 2020-08-14 Basf Beauty Care Solutions France Sas Utilisation d'un extrait de nephelium lappaceum pour augmenter la fermete de la peau et/ou des muqueuses
CA3099077A1 (en) 2017-07-13 2019-01-17 Michael David FORREST Therapeutic modulators of the reverse mode of atp synthase
EP3661538A4 (en) 2017-08-03 2021-07-14 Alastin Skincare, Inc. COMPOSITIONS AND PROCEDURES FOR IMPROVING SLEEPING SKIN AND BODY CONTOUR
CN108004282B (zh) * 2017-12-01 2021-02-05 中国农业科学院麻类研究所 一种制备灵芝子实体发酵物的方法、发酵物及其应用
WO2020028694A1 (en) 2018-08-02 2020-02-06 ALASTIN Skincare, Inc. Liposomal compositions and methods of use
WO2020056191A1 (en) 2018-09-13 2020-03-19 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
IT201900008364A1 (it) * 2019-06-07 2020-12-07 Espikem S R L Peptidi bioattivi e composizioni che li comprendono
GB2586577B (en) * 2019-06-14 2024-03-27 Gelmetix Ltd Diagnosis and treatment
CN111596069B (zh) * 2020-06-03 2021-08-06 四川大学华西第二医院 Hsp10在pop早期预警、诊断、预后评估中的应用和产品
IL295386A (en) * 2020-07-29 2022-10-01 Karnak Tech Llc Improved formulations of lipophilic subtances for cosmetic uses
WO2022076713A1 (en) * 2020-10-08 2022-04-14 ALASTIN Skincare, Inc. Compositions and methods relating to stimulation of hyaluronic acid
US12223536B2 (en) * 2020-10-19 2025-02-11 Lillycover Co., Ltd. Method for providing customized cosmetic product service
US20250325469A1 (en) 2021-01-24 2025-10-23 Michael David FORREST Inhibitors of atp synthase - cosmetic and therapeutic uses
CN115670965B (zh) * 2021-05-17 2024-04-19 杭州朝与暮品牌管理有限公司 一种有效抑制IL-8、TNF-α和IL-6的皮肤抗炎组合物
FR3126309B1 (fr) * 2021-08-30 2024-03-08 Oreal COMPOSITION COSMÉTIQUE à BASE DE GLAUCINE, RETINOL ET PEPTIDES POUR COMBATTRE LE VIEILLISSEMENT DE LA PEAU
CN113876641A (zh) * 2021-11-05 2022-01-04 上海新高姿化妆品有限公司 一种具有抗皱紧致功效的化妆品组合物及其应用
KR102792530B1 (ko) * 2021-12-27 2025-04-08 (주)케어젠 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도
CN116120402B (zh) * 2022-11-04 2024-03-15 深圳市维琪科技股份有限公司 一种环肽及其组合物和用途
CN115594735B (zh) * 2022-11-25 2023-09-22 深圳市维琪科技股份有限公司 具有抗衰老作用的肽及其组合物和用途
CN116440019B (zh) * 2023-03-27 2024-12-27 广东馨柯生命科学有限公司 含咖啡豆发酵液醒肤咖Supferm COFE和活力咖的防脱生发出水霜及其制备方法
WO2024229256A1 (en) * 2023-05-03 2024-11-07 Glo Pharma, Inc. Methods and compositions for cosmetic applications
CN117338628B (zh) * 2023-12-05 2024-04-09 杭州湃肽生化科技有限公司 一种紧肤抗皱组合物及其应用
CN119080885B (zh) * 2023-12-26 2025-09-12 杭州湃肽生化科技有限公司 环九肽-1及其制备方法及应用
WO2026029259A1 (ko) * 2024-07-31 2026-02-05 주식회사 바이오비쥬 트로포엘라스틴 가교 활성을 갖는 생체 적합성 폴리머를 포함하는 조성물
CN119462983B (zh) * 2024-11-13 2025-09-23 成都大学 一种大枣改性酸性多糖及其制备方法和用途
CN119241661B (zh) * 2024-11-14 2025-08-01 云南贝泰妮生物科技集团股份有限公司 一种具有抗炎作用的环肽化合物及其制备方法和应用
KR102782681B1 (ko) * 2024-12-16 2025-03-19 주식회사 바이오비쥬 트로포엘라스틴 가교 활성을 갖는 생체 적합성 폴리머를 포함하는 기능성 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050188427A1 (en) 2004-01-23 2005-08-25 Tiansen Li Lysyl oxidase-like 1 (LOXL1) and elastogenesis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126788A1 (en) 2002-08-13 2004-07-01 Schiemann William P. Fibulin-5 and uses thereof
US7943590B2 (en) 2007-03-16 2011-05-17 Multi-Gene Vascular Systems Ltd. Compositions and methods for treating ophthalmic disorders
EP2740484A1 (en) * 2012-12-05 2014-06-11 Lipotec, S.A. Compounds useful in the treatment and/or care of the skin, hair and/or muccous membranes and their cosmetic or pharmaceutical compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050188427A1 (en) 2004-01-23 2005-08-25 Tiansen Li Lysyl oxidase-like 1 (LOXL1) and elastogenesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
N. Hermida et al., Cardiovascular Research, Vol. 81, Iss. 3, pp. 601-609 (2009.02.15.)

Also Published As

Publication number Publication date
AU2014255776A1 (en) 2015-10-22
US9458194B2 (en) 2016-10-04
CA2908863C (en) 2022-07-12
US20160075738A1 (en) 2016-03-17
JP2016519105A (ja) 2016-06-30
BR112015025961A2 (pt) 2017-10-17
EP2986626B1 (en) 2017-06-07
JP6525433B2 (ja) 2019-06-05
CN105408345B (zh) 2020-08-07
CN105408345A (zh) 2016-03-16
EP2986626A1 (en) 2016-02-24
AU2014255776B2 (en) 2018-09-06
KR20150143752A (ko) 2015-12-23
CA2908863A1 (en) 2014-10-23
ES2639464T3 (es) 2017-10-26
EP2792684A1 (en) 2014-10-22
WO2014170347A1 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
JP6525433B2 (ja) 皮膚の処置および/またはケアにおいて有用な化合物ならびにその美容的または薬学的組成物
JP7227903B2 (ja) 皮膚、毛髪、爪および/もしくは粘膜の処置ならびに/またはケアに有用な化合物
JP5864425B2 (ja) 皮膚、粘膜および/または毛髪の治療および/またはケアに使用するペプチド、ならびに化粧料または医薬品組成物におけるその使用
KR102285933B1 (ko) 피부, 모발 및/또는 점막의 치료 및/또는 관리에 유용한 화합물 및 이들의 미용적 또는 약제학적 조성물
CN102317307B (zh) 用于治疗和/或护理皮肤、粘膜和/或头皮的肽及它们在美容组合物或药物组合物中的用途
CN104023737B (zh) 抑制被激活受体的肽及其在化妆品组合物或药物组合物中的用途
CN103314005B (zh) 在皮肤和/或粘膜的治疗和/或护理中有用的肽以及它们在化妆品组合物或药用组合物中的用途
KR102797328B1 (ko) 피부, 모발, 손톱 및/또는 점막의 치료 및/또는 관리에 유용한 화합물
JP5782439B2 (ja) 筋肉収縮を抑制する化合物
JP7526159B2 (ja) 皮膚、毛髪、爪および/または粘膜の処置および/またはケアに有用な化合物
CN108495646A (zh) 用于治疗和/或护理皮肤、毛发、指甲和/或粘膜的化合物
CN116829169A (zh) 一种合成肽以及它们的美容组合物或药用组合物及用途
BR112015025961B1 (pt) Composto, composição cosmética ou farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6